39P - Prognostic and predictive value of CD8 + , CD4 + infiltration and KI-67 level in the post-chemotherapy residual disease in triple negative breast ca...

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Immunotherapy
Breast Cancer
Therapy
Presenter Nataliia Verovkina
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors N.O. Verovkina1, L.A. Syvak2, S. Lyalkin2, N.M. Majdanevych2, A. Askolsky2, M.U. Klimanov2, N.V. Kasap2, O.M. Grabovyy3, M.S. Krotevych3
  • 1Research Department Of Chemotherapy Solid Tumors, National Cancer Institute of the MPH Ukraine, Kiev, UA, 03022 - Kyiv/UA
  • 2Research Department Of Chemotherapy Solid Tumors, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA
  • 3Research Department Of The Pathological Anatomy And Histology, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA

Abstract

Aim

To assess the prognostic and predictive value of СD3 + , CD4+ and CD8+ infiltration and Ki-67 levels in the residual disease in TNBC.

Methods

Treatment results of 25 patients with TNBC stages ІІВ-ІІІВ treated with neoadjuvant chemotherapy were analyzed. We studied the post-treatment CD3 + , CD4 + , CD8+ tumor-infiltrating immune cells and Ki-67 positive cells by immunohistochemistry. Immune cell profiles and Ki-67 levels were found to correlate with response and survival.

Results

Pathological complete response (pCR) to neoadjuvant chemotherapy was identified in 48% of patients. High levels of the tumor infiltrating CD3+ cells were identified in 20% of patients; high levels of the CD4+ cells were identified in 44% of patients; high levels of CD8+ cells were identified in 28% of patients. 84% of patients had a high level of Ki-67 in the residual tumor. Occurrence of pCR was found to correlate with low Ki-67 levels (p = 0.02) and high levels of CD8+ (p = 0.04). The group of patients without pCR had high levels of Ki-67 and low levels of tumor infiltrating CD8+ cells. High levels of CD4+ cells were associated with high risk of not achieving pCR (OR = 2.3). Median disease free interval (DFI) was 17 ± 9.2 months. Longer DFI was associated with high levels of CD8+ positive cells in residual tumor (r = 0.53, р = 0.075); shorter DFI was associated with high levels of Ki-67 (r = 0.37, р < 0.1). Interestingly, worsening overall survival trend was observed in the group of patients with high levels of Ki-67 and CD8+ cells in residual tumor (p = 0.05). The improved overall survival correlated with increasing CD4+ and CD8+ infiltration in residual tumor (r = 0.39, р = 0.03). A higher risk of death was observed in patients with high levels of CD4+ infiltration (OR = 14.6) and high levels of Ki-67 in residual tumor (OR = 7.7).

Conclusions

Preliminary results of the study indicate that understanding of the interaction between breast cancer cells and immune cells could allow identifying patients who are likely to benefit from immunotherapeutic adjuvants to conventional treatment approaches.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.